8 withdrawn. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Withdrawn 8 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19) ACE2 Chewing Gum, Placebo Chewing Gum - SARS-CoV-2 | Phase 1 / Phase 2 | Withdrawn | University of Pennsylvania | 2025-02-01 | 2025-03-30 | |
| SARS-CoV-2 Safety Study for the Treatment of COVID-19 HIV, Malignant Neoplasms Safety Study for the Treatment of Neoplasms - SARS-CoV-2 | Phase 2 | Withdrawn | DHA Coffee Co., Ltd | 2025-01-28 | 2025-09-04 | |
| A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine UB-612, Placebo - Covid-19, SARS-CoV-2 | Phase 2 / Phase 3 | Withdrawn | Vaxxinity, Inc. | 2021-02-01 | 2022-04-04 | |
| Interferon Lambda Therapy for COVID-19 Peginterferon Lambda-1A - SARS-CoV-2 | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2020-09-01 | 2021-02-26 | |
| Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) Hydroxychloroquine, Placebo - COVID-19, SARS-CoV-2 | Phase 2 | Withdrawn | Oregon Health and Science University | 2020-08-01 | 2020-10-29 | |
| RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM Doxycycline, Placebo - Cytokine Storm, SARS-CoV-2 | Phase 2 | Withdrawn | Temple University | 2020-06-22 | 2021-04-19 | |
| A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Hydroxychloroquine, Placebo - COVID-19, COVID19 | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2020-05-05 | 2025-05-16 | |
| Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women hydroxychloroquine sulfate 200 MG, Placebo oral tablet - COVID-19, SARS-CoV-2 | Phase 2 | Withdrawn | Sir Mortimer B. Davis - Jewish General Hospital | 2020-05-01 | 2020-06-25 |
COVID-19 (4) · Coronavirus Infections (2) · Cytokine Release Syndrome (1)
Coronaviridae Infections (4) · Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Virus Diseases (4) · Coronavirus Infections (2) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Shock (1)
Hydroxychloroquine (3) · Doxycycline (1) · Interferon Lambda (1) · UB-612 COVID-19 vaccine (1) · peginterferon lambda-1a (1)
DHA Coffee Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1) · Memorial Sloan Kettering Cancer Center (1) · Oregon Health and Science University (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Temple University (1) · University of Pennsylvania (1) · Vaxxinity, Inc. (1)
United States (4)
Arthur M Feldman, MD, PhD (1) · Genovefa Papanicolaou, MD (1) · Gray Heppner (1) · Marcel Curlin, MD (1) · Thomas Marron, MD (1)